BRIEF—UK PIM designation for rezafungin in invasive candidiasis

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted rezafungin, a once-weekly echinocandin, Promising Innovative Medicine (PIM) designation for the treatment of invasive candidiasis.

Rezafungin is being developed by Cidara Therapeutics in partnership with Mundipharma, which has commercial rights outside the USA and Japan.

Brian Sheehan, chief scientific officer at Mundipharma, said: “Despite currently available treatments, the mortality rate for patients with invasive candidiasis remains high, demonstrating that there is still a clear unmet need for new treatment options to address this serious disease.

“Rezafungin, as a next generation echinocandin, has the potential to help critically ill, vulnerable patients battling invasive Candida infections. We would like to thank the MHRA for this recognition and look forward to working closely with them to ensure that patients in the UK can benefit from rezafungin.”